Terms: = Lung cancer AND KEAP1, INrf2, ENSG00000079999, 9817, Q14145, MGC9454, MGC4407, MGC20887, MGC1114, MGC10630, KLHL19, KIAA0132
400 results:
1. Development, testing and validation of a targeted NGS-panel for the detection of actionable mutations in lung cancer (NSCLC) using anchored multiplex PCR technology in a multicentric setting.
Kumbrink J; Demes MC; Jeroch J; Bräuninger A; Hartung K; Gerstenmaier U; Marienfeld R; Hillmer A; Bohn N; Lehning C; Ferch F; Wild P; Gattenlöhner S; Möller P; Klauschen F; Jung A
Pathol Oncol Res; 2024; 30():1611590. PubMed ID: 38605929
[TBL] [Abstract] [Full Text] [Related]
2. Redox
Wei XW; Lu C; Zhang YC; Fan X; Xu CR; Chen ZH; Wang F; Yang XR; Deng JY; Yang MY; Gou Q; Mei SQ; Luo WC; Zhong RW; Zhong WZ; Yang JJ; Zhang XC; Tu HY; Wu YL; Zhou Q
Oncoimmunology; 2024; 13(1):2340154. PubMed ID: 38601319
[TBL] [Abstract] [Full Text] [Related]
3.
Occhiuto CJ; Liby KT
Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542481
[TBL] [Abstract] [Full Text] [Related]
4. Glutamine antagonist DRP-104 suppresses tumor growth and enhances response to checkpoint blockade in
Pillai R; LeBoeuf SE; Hao Y; New C; Blum JLE; Rashidfarrokhi A; Huang SM; Bahamon C; Wu WL; Karadal-Ferrena B; Herrera A; Ivanova E; Cross M; Bossowski JP; Ding H; Hayashi M; Rajalingam S; Karakousi T; Sayin VI; Khanna KM; Wong KK; Wild R; Tsirigos A; Poirier JT; Rudin CM; Davidson SM; Koralov SB; Papagiannakopoulos T
Sci Adv; 2024 Mar; 10(13):eadm9859. PubMed ID: 38536921
[TBL] [Abstract] [Full Text] [Related]
5. Glutamine antagonists may KEAP lung cancer in check.
Blatt EB; DeBerardinis RJ
Sci Adv; 2024 Mar; 10(13):eado7808. PubMed ID: 38536918
[TBL] [Abstract] [Full Text] [Related]
6. AURKA emerges as a vulnerable target for keap1-deficient non-small cell lung cancer by activation of asparagine synthesis.
Deng B; Liu F; Chen N; Li X; Lei J; Chen N; Wu J; Wang X; Lu J; Fang M; Chen A; Zhang Z; He B; Yan M; Zhang Y; Wang Z; Liu Q
Cell Death Dis; 2024 Mar; 15(3):233. PubMed ID: 38521813
[TBL] [Abstract] [Full Text] [Related]
7. Outcomes in patients treated with frontline immune checkpoint inhibition (ICI) for advanced NSCLC with KRAS mutations and STK11/keap1 comutations across PD-L1 levels.
Sun L; Handorf EA; Zhou Y; Borghaei H; Aggarwal C; Bauman J
Lung Cancer; 2024 Apr; 190():107510. PubMed ID: 38432028
[TBL] [Abstract] [Full Text] [Related]
8. keap1 promotes anti-tumor immunity by inhibiting PD-L1 expression in NSCLC.
Li J; Shi D; Li S; Shi X; Liu Y; Zhang Y; Wang G; Zhang C; Xia T; Piao HL; Liu HX
Cell Death Dis; 2024 Feb; 15(2):175. PubMed ID: 38413563
[TBL] [Abstract] [Full Text] [Related]
9. Postoperative ctDNA in indicating the recurrence risk and monitoring the effect of adjuvant therapy in surgical non-small cell lung cancer.
Tian X; Liu X; Wang K; Wang R; Li Y; Qian K; Wang T; Zhao X; Liu L; Zhang PL; Xiong Y; Rui J; Chen R; Zhang Y
Thorac Cancer; 2024 Apr; 15(10):797-807. PubMed ID: 38409945
[TBL] [Abstract] [Full Text] [Related]
10. Sotorasib in KRAS G12C-mutated non-small cell lung cancer: A multicenter real-world experience from the compassionate use program in Germany.
Stratmann JA; Althoff FC; Doebel P; Rauh J; Trummer A; Hünerlitürkoglu AN; Frost N; Yildirim H; Christopoulos P; Burkhard O; Büschenfelde CMZ; Becker von Rose A; Alt J; Aries SP; Webendörfer M; Kaldune S; Uhlenbruch M; Tritchkova G; Waller CF; Rittmeyer A; Hoffknecht P; Braess J; Kopp HG; Grohé C; Schäfer M; Schumann C; Griesinger F; Kuon J; Sebastian M; Reinmuth N
Eur J Cancer; 2024 Apr; 201():113911. PubMed ID: 38377774
[TBL] [Abstract] [Full Text] [Related]
11. Combining Genomic Biomarkers to Guide Immunotherapy in Non-Small Cell lung cancer.
van de Haar J; Mankor JM; Hummelink K; Monkhorst K; Smit EF; Wessels LFA; Cuppen E; Aerts JGJV; Voest EE
Clin Cancer Res; 2024 Apr; 30(7):1307-1318. PubMed ID: 38300729
[TBL] [Abstract] [Full Text] [Related]
12. [Clinicopathological features of SMARCA4-deficient lung adenocarcinoma: a study of 42 cases].
Han J; Gao XZ; Xu Y; Liu EJ; Du Q; Chen K; Li SL
Zhonghua Bing Li Xue Za Zhi; 2024 Feb; 53(2):136-142. PubMed ID: 38281780
[No Abstract] [Full Text] [Related]
13. Transcription Silencing and CpGs Hypermethylation as Therapeutic Gene Editing in Clinical Colorectal Adenocarcinoma Repression.
Al-Jumaili MMO
Korean J Gastroenterol; 2024 Jan; 83(1):6-16. PubMed ID: 38268163
[TBL] [Abstract] [Full Text] [Related]
14. Genome-wide analyses reveal the contribution of somatic variants to the immune landscape of multiple cancer types.
Bi W; Xu Z; Liu F; Xie Z; Liu H; Zhu X; Zhong W; Zhang P; Tang X
PLoS Genet; 2024 Jan; 20(1):e1011134. PubMed ID: 38241355
[TBL] [Abstract] [Full Text] [Related]
15. Genomic and Immunophenotypic Landscape of Acquired Resistance to PD-(L)1 Blockade in Non-Small-Cell lung cancer.
Ricciuti B; Lamberti G; Puchala SR; Mahadevan NR; Lin JR; Alessi JV; Chowdhury A; Li YY; Wang X; Spurr L; Pecci F; Di Federico A; Venkatraman D; Barrichello AP; Gandhi M; Vaz VR; Pangilinan AJ; Haradon D; Lee E; Gupta H; Pfaff KL; Welsh EL; Nishino M; Cherniack AD; Johnson BE; Weirather JL; Dryg ID; Rodig SJ; Sholl LM; Sorger P; Santagata S; Umeton R; Awad MM
J Clin Oncol; 2024 Apr; 42(11):1311-1321. PubMed ID: 38207230
[TBL] [Abstract] [Full Text] [Related]
16. Outcomes following KRAS
Chen QA; Lin WH; Zhou XX; Cao Z; Feng XL; Gao YB; He J
Pharmacol Res; 2024 Feb; 200():107060. PubMed ID: 38185210
[TBL] [Abstract] [Full Text] [Related]
17. Oncogenic keap1 mutations activate TRAF2-NFκB signaling to prevent apoptosis in lung cancer cells.
Deen AJ; Adinolfi S; Härkönen J; Patinen T; Liu X; Laitinen T; Takabe P; Kainulainen K; Pasonen-Seppänen S; Gawriyski LM; Arasu UT; Selvarajan I; Mäkinen P; Laitinen H; Kansanen E; Kaikkonen MU; Poso A; Varjosalo M; Levonen AL
Redox Biol; 2024 Feb; 69():103031. PubMed ID: 38184997
[TBL] [Abstract] [Full Text] [Related]
18. Interplay of oxidative stress, cellular communication and signaling pathways in cancer.
Iqbal MJ; Kabeer A; Abbas Z; Siddiqui HA; Calina D; Sharifi-Rad J; Cho WC
Cell Commun Signal; 2024 Jan; 22(1):7. PubMed ID: 38167159
[TBL] [Abstract] [Full Text] [Related]
19. Genomic Landscape of Pulmonary Sarcomatoid Carcinoma.
Kwon HJ; Lee S; Han YB; Lee J; Kwon S; Kim H; Chung JH
Cancer Res Treat; 2024 Apr; 56(2):442-454. PubMed ID: 37973906
[TBL] [Abstract] [Full Text] [Related]
20. keap1 mutation in lung adenocarcinoma promotes immune evasion and immunotherapy resistance.
Zavitsanou AM; Pillai R; Hao Y; Wu WL; Bartnicki E; Karakousi T; Rajalingam S; Herrera A; Karatza A; Rashidfarrokhi A; Solis S; Ciampricotti M; Yeaton AH; Ivanova E; Wohlhieter CA; Buus TB; Hayashi M; Karadal-Ferrena B; Pass HI; Poirier JT; Rudin CM; Wong KK; Moreira AL; Khanna KM; Tsirigos A; Papagiannakopoulos T; Koralov SB
Cell Rep; 2023 Nov; 42(11):113295. PubMed ID: 37889752
[TBL] [Abstract] [Full Text] [Related]
[Next]